Diabetic Neuropathic Pain Market to Grow with a CAGR of 5.68% through 2030F
Raising awareness about diabetic neuropathic pain and its
management are expected to drive the Global Diabetic Neuropathic Pain Market
growth in the forecast period, 2026-2030.
According to TechSci Research report,
“Diabetic Neuropathic Pain Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global
Diabetic Neuropathic Pain Market stood at USD 1.64 billion in 2024 and is
anticipated to grow with a CAGR of 5.68% in the forecast period, 2026-2030.
The Global Diabetic Neuropathic Pain Market is experiencing
significant growth driven by a confluence of factors that are reshaping the
landscape of diabetes care. Diabetic neuropathic pain is a distressing
complication of diabetes mellitus, characterized by nerve damage that results
in chronic pain and discomfort for patients. As the prevalence of diabetes
continues to rise globally, so too does the incidence of diabetic neuropathy,
fueling the demand for effective pain management solutions. The foremost driver
of the Global Diabetic Neuropathic Pain Market is the escalating diabetes
epidemic. Diabetes mellitus has reached pandemic proportions, with millions of
individuals worldwide diagnosed with this chronic condition. According to the
International Diabetes Federation (IDF), there were approximately 463 million
adults living with diabetes in 2019, a number projected to rise to 700 million
by 2045. As diabetes prevalence increases, so does the pool of patients at risk
of developing diabetic neuropathy, the most common cause of neuropathic pain in
diabetics. This ever-expanding patient base is a primary driver for the
market's growth.
The global aging population is another significant factor
contributing to the expansion of the diabetic neuropathic pain market. With
increasing life expectancies, there is a greater likelihood of individuals
developing diabetes and its associated complications as they age. Older adults
are more susceptible to diabetic neuropathy, making them a substantial segment
of the patient population in need of pain management solutions. As the
demographic shift towards an older population continues, the market for diabetic
neuropathic pain management is expected to expand further.
Pharmaceutical companies have been instrumental in driving
innovation within the diabetic neuropathic pain market. There is a continuous
quest for more effective and safer medications to alleviate the debilitating
pain experienced by diabetic neuropathy patients. Anticonvulsants,
antidepressants, and opioids are among the commonly prescribed pharmaceuticals
for managing neuropathic pain. However, the market is witnessing the
development of novel drugs with improved efficacy and reduced side effects. These
advancements not only provide better pain relief but also expand the treatment
options available to healthcare providers and patients.
In addition to pharmaceuticals, non-pharmacological approaches to diabetic neuropathic pain management are gaining prominence. These approaches include neurostimulation devices, physical therapy, and lifestyle modifications. Neurostimulation devices, such as spinal cord stimulators and peripheral nerve stimulators, offer an alternative to medication and have shown promising results in pain reduction. Physical therapy helps patients improve their mobility and manage pain through exercise and rehabilitation programs. Lifestyle modifications, including dietary changes and blood sugar control, are essential in preventing and managing diabetic neuropathy. The growing interest in non-pharmacological treatments is diversifying the market and offering patients more comprehensive care options.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Diabetic Neuropathic Pain Market”
The Global Diabetic Neuropathic Pain Market is segmented
into type, route of administration, distribution channel, regional
distribution, and company.
Based on the neuropathy type, Peripheral Neuropathy became the fastest-growing segment in the Global Diabetic Neuropathic Pain Market in 2024. Its high prevalence is primarily due to the chronic nature of diabetes, especially when blood sugar levels remain poorly controlled over time. Prolonged exposure to high glucose levels can cause nerve damage, leading to neuropathic pain. As diabetes incidence rises globally, so does the number of individuals at risk, driving increased demand for pain management solutions and treatments..
Based on region, Asia-Pacific region is experiencing rapid
growth in the global diabetic neuropathic pain market, driven by several key
factors. Firstly, there's a significant increase in diabetes prevalence,
particularly in countries like India, China, and Japan, leading to a higher
incidence of diabetic neuropathy. Secondly, advancements in healthcare
infrastructure have improved access to diagnostic and treatment facilities,
enabling better management of neuropathic pain. The rising public and medical
awareness about neuropathic pain has led to earlier diagnoses and timely
interventions. Economic growth in the region has also increased disposable
incomes, making advanced treatments more accessible to a larger population
segment. The adoption of non-invasive therapies, such as Transcutaneous
Electrical Nerve Stimulation (TENS) and spinal cord stimulators, offers
effective alternatives to traditional pain management methods. Collectively,
these factors contribute to the accelerated expansion of the diabetic
neuropathic pain market in the Asia-Pacific region.
Major companies operating in Global Diabetic
Neuropathic Pain Market are:
- Eli Lilly and Company
- Grunenthal GmBH
- Collegium Pharmaceutical, Inc.
- Lupin Ltd
- Daiichi Sankyo Inc.
- Azurity Pharmaceuticals, Inc.
- Novartis AG
- Pfizer, Inc.
- Endo International plc. (Par Pharmaceutical)
- Johnson & Johnson
Download Free Sample Report
Customers can also request for 10% free customization on
this report.
“The Global Diabetic Neuropathic Pain Market is poised for
significant growth in the coming years due to several compelling factors.
Firstly, advancements in personalized medicine approaches are expected to
revolutionize lipodystrophy treatment by tailoring therapies to individual
patient characteristics, enhancing treatment efficacy, and improving overall
patient outcomes. Secondly, the market is witnessing a surge in innovative
therapies and interventions specifically designed to address the complexities of
lipodystrophy, offering new hope for individuals living with this condition.
Besides, increased patient advocacy and awareness campaigns are driving early
diagnosis, timely intervention, and improved access to care, thus bolstering
market demand. Lastly, the integration of lipodystrophy management into routine
HIV care programs is facilitating early diagnosis and a more holistic approach
to treatment, contributing to market growth.” said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“Diabetic Neuropathic Pain Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Neuropathy Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), Drug Class (Antidepressants, Anticonvulsants, Analgesics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Competition 2020-2030F”, has evaluated the future growth
potential of Global Diabetic Neuropathic Pain Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Diabetic Neuropathic Pain Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com